Clinical trials sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Phase breakdown

Conditions studied

Recruiting trials led by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

• A Bioequivalence Study of PP3M in Patients With Schizophrenia
  NCT07493551 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
  NCT07465263 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
  NCT07421297 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia
  NCT07591298 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials is CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. recruiting for?

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. is the lead sponsor of 4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.